Tuesday, 24 April 2018 - 0:09
  • it
  • de
  • en
  • fr

Shire

Pfizer signs $160m cooperation agreement with Sangamo Therapeutics

Pfizer and Sangamo Therapeutics have announced a cooperation aimed at using the “zinc finger therapy” for the treatment of ALS linked to mutations of the C9ORF72 gene. Thanks to the agreement, Sangamo will receive $12m from Pfizer, plus a potential…

Shire announces reorganization plans in United States

Shire announced the plans for its US branch in terms of company reorganization. The Ireland-based group will focus its resources on two plants: Cambridge, Massachusetts (HQ) and Lexington (for biologic drugs). This is likely to result in the company closing…

EMA validates MAA for Shire’s Veyvondi for Von Willebrand disease

Shire announced that EMA validated the MAA (Marketing Authorization Application) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adult patients diagnosed with von Willebrand Disease (VWD). VWD is the most common bleeding disorder and affects up…

Surprising Shire: very good results for lanadelumab, shares soar

Shire’s shares rose over 7% in pre-market trading (Nasdaq) as CEO Flemming Ornskov announced highly positive Phase III results from HELP clinical trial, assessing lanadelumab for the treatment of hereditary angioedema (HAE). The study, conducted on 125 patients over 26…

Shire’s Natpar close to commercialization

Pharmaceutical group Shire announced in a press release that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on Natpar, a recombinant parathyroid hormone with an 84–amino-acid sequence, as…

Record results from Shire (2016)

Shire, a company specialized in rare disease treatments, reported today its 2016 financial results. 2016 was a highly positive year for Shire. It started with the $32bn acquisition of Baxalta, which contributed 78% of 2016 total sales. Total revenues were…

FDA approves Shire’s Adynovate

Shire announced that FDA has approved Adynovate, a treatment for hemophilia A, in pediatric patients under 12 years of age. The product has been approved also for use in surgical settings for both adult and pediatric patients. The approval for…

Positive results for Shire’s Vonvendi

Shire today announced the results from a Phase-III clinical trial aimed at evaluating Vonvendi [von Willebrand factor (Recombinant)], in terms of hemostatic efficacy and safety, in treating bleeds in elective surgical settings for adults with severe von Willebrand disease. Vonvendi…